Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients

被引:14
作者
Kim, Sehwa [1 ,2 ]
Lee, Yoonseok [1 ]
Bang, Soo Min [1 ]
Bak, Haein [1 ]
Yim, Sun Young [1 ]
Lee, Young Sun [1 ]
Yoo, Yang Jae [2 ]
Jung, Young Kul [1 ]
Kim, Ji Hoon [1 ]
Seo, Yeon Seok [1 ]
Yim, Hyung Joon [1 ]
Um, Soon Ho [1 ]
Byun, Kwan Soo [1 ]
Yeon, Jong Eun [1 ]
机构
[1] Korea Univ, Dept Internal Med, Coll Med, Seoul 08308, South Korea
[2] Bundang Jesaeng Gen Hosp, Dept Internal Med, Seongnam Si 13590, South Korea
基金
新加坡国家研究基金会;
关键词
alt normalization; hcc; entecavir; tenofovir; CHRONIC HEPATITIS-B; VIRUS INFECTION; LIVER; CIRRHOSIS; EPIDEMIOLOGY; MANAGEMENT; DNA;
D O I
10.3390/jcm10091840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Potent antiviral agents effectively reduce liver-related events in patients with chronic hepatitis B. This study aimed to determine whether alanine aminotransferase normalization using potent antiviral agents was related to hepatocellular carcinoma development. From 2007 to 2017, we included 610 patients with chronic hepatitis B who received entecavir or tenofovir disoproxil fumarate. The patients were divided into the alanine aminotransferase normalization group (Gr.1) and non-normalization group (Gr.2) within a year of potent antiviral treatment. Liver-related events included hepatic encephalopathy, variceal bleeding, and ascites. The mortality rate and hepatocellular carcinoma incidence were investigated for each group. The patients who showed ALT normalization at 1 year of treatment were 397 (65.1%) of 610. During a median follow-up period of 86 months, 65 (10.7%) patients developed hepatocellular carcinoma. The cumulative incidence of hepatocellular carcinoma was significantly lower in Gr.1 than in Gr.2 (p < 0.001). Risk factors for alanine aminotransferase non-normalization were body mass index, cholesterol, and liver cirrhosis at baseline. Male sex, age, platelet level, alcohol use, presence of cirrhosis at baseline, and non-normalization after 1 year of treatment were independent risk factors for hepatocellular carcinoma. Alanine aminotransferase normalization within 1 year of initiating antiviral agents reduces the risk of hepatocellular carcinoma development.
引用
收藏
页数:15
相关论文
共 34 条
[1]   Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis [J].
Berzigotti, Annalisa ;
Abraldes, Juan G. ;
Tandon, Puneeta ;
Erice, Eva ;
Gilabert, Rosa ;
Carlos Garcia-Pagan, Juan ;
Bosch, Jaime .
JOURNAL OF HEPATOLOGY, 2010, 52 (06) :846-853
[2]  
Buti M., Lancet Gastroenterol Hepatol
[3]   Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial [J].
Chan, Henry L. Y. ;
Fung, Scott ;
Seto, Wai Kay ;
Chuang, Wan-Long ;
Chen, Chi-Yi ;
Kim, Hyungjoon ;
Hui, Aric Josun ;
Janssen, Harry L. A. ;
Chowdhury, Abhijit ;
Tsang, Tak Yin Owen ;
Mehta, Rajiv ;
Gane, Edward ;
Flaherty, John F. ;
Massetto, Benedetta ;
Gaggar, Anuj ;
Kitrinos, Kathryn M. ;
Lin, Lanjia ;
Subramanian, G. Mani ;
McHutchison, John G. ;
Lim, Young-Suk ;
Acharya, Subrat K. ;
Agarwal, Kosh .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03) :185-195
[4]   Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma [J].
Chen, Chuen-Fei ;
Lee, Wen-Chung ;
Yang, Hwai-I ;
Chang, Hung-Chuen ;
Jen, Chin-Lan ;
Iloeje, Uchenna H. ;
Su, Jun ;
Hsiao, Chuhsing K. ;
Wang, Li-Yu ;
You, San-Lin ;
Lu, Sheng-Nan ;
Chen, Chien-Jen .
GASTROENTEROLOGY, 2011, 141 (04) :1240-U662
[5]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[6]   HBV-Induced Immune Imbalance in the Development of HCC [J].
Chen, Yongyan ;
Tian, Zhigang .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[7]   Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B [J].
Choi, Jonggi ;
Kim, Gi-Ae ;
Han, Seungbong ;
Lim, Young-Suk .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (03) :406-414
[8]   RETRACTED: Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study (Retracted Article) [J].
Choi, Jonggi ;
Kim, Hyo Jeong ;
Lee, Jayoun ;
Cho, Songhee ;
Ko, Min Jung ;
Lim, Young-Suk .
JAMA ONCOLOGY, 2019, 5 (01) :30-36
[9]   Does antiviral therapy reduce complications of cirrhosis? [J].
Chung, Goh Eun ;
Lee, Jeong-Hoon ;
Kim, Yoon Jun .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) :7306-7311
[10]   Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review [J].
Desai, Aakash ;
Sandhu, Sonia ;
Lai, Jin-Ping ;
Sandhu, Dalbir Singh .
WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (01) :1-18